Topics

Shape Therapeutics raises $35.5M Series A round to develop RNA-based gene editing technology

08:05 EST 8 Nov 2019 | MedCity News

The company said its technology could avoid the risk of in vivo immunogenicity and permanent off-target damage associated with CRISPR/Cas9 gene-editing approaches.

Original Article: Shape Therapeutics raises $35.5M Series A round to develop RNA-based gene editing technology

NEXT ARTICLE

More From BioPortfolio on "Shape Therapeutics raises $35.5M Series A round to develop RNA-based gene editing technology"

Quick Search

Relevant Topic

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...